Navigation Links
Helix BioPharma announces Q1 2008 financial results
Date:12/17/2007

d L-DOS47 product candidates continue to be developed.

Operating, general & administration

Operating, general and administration expenses in the first quarter of fiscal 2008 totaled $1,313,000 (2007 - $906,000), for an increase of $407,000. The increase is mainly attributable to a one time charge of $434,000 relating to the resignation of the Company's Chairman.

Amortization of intangible and capital assets

Amortization of intangible assets in the first quarter of fiscal 2008 totaled $7,000 (2007 - $40,000). The variance is due to certain intangible assets which have now been fully amortized. Amortization of capital assets in first quarter of fiscal 2008 totaled $66,000 (2007 - $77,000).

Stock-based compensation

Stock-based compensation expense in the first quarter of fiscal 2008 totalled $12,000 (2007 - $12,000). The stock-based compensation expense relates to the ongoing amortization of compensation costs of stock options granted on June 30, 2005, over their vesting period.

Interest income

Interest income in the first quarter of fiscal 2008 totaled $104,000 and remained flat when compared to the first quarter of fiscal 2007 which totaled $102,000.

Foreign exchange loss

Foreign exchange losses in the first quarter of fiscal 2008 totaled $108,000 (2007 - $45,000). Foreign exchange losses resulting from the foreign currency translation of the Company's integrated foreign operation in Ireland were offset by foreign exchange gains related to the Canadian dollar appreciation versus the U.S. dollar. The Company's net assets in Europe consist mainly of cash and cash equivalents, denominated in Euro currency and are used to fund clinical trials of Topical Interferon Alpha-2b in Europe.

Income taxes

Income tax expense in the first quarter of fiscal 2008 totaled $32,000 (2007 - $29,000). All income taxes are attributable to the Company's operations in Europe.

Other comprehensive income
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
11. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
(Date:12/19/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today ... privately held company based in Redwood ... big data platform for centralized management and processing ... on-market Genomic Management Solution, Bina-GMS 1 , empowers ... and scalable analyses to maximize the value of ...
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... New Service Helps Customers to Treat More Patients, ... ARAY ), a global leader in the ... begin offering a treatment planning,service to new and ... centers to access a dedicated team of remote ...
... Quintiles,Transnational Corp. today announced the completion of ... company,s continued,growth under the leadership of founder and ... management team. Gillings and global private,investment firms Bain ... in Quintiles, with 3i also becoming a significant ...
... Ind., Jan. 23 Zimmer Holdings, Inc.,(NYSE: ZMH ... announced,today it will be participating in the Wachovia Securities ... 10:15 a.m. Eastern Time., A live webcast of ... at http://investor.zimmer.com . The webcast will,be archived for ...
Cached Biology Technology:Accuray Announces New Treatment Planning Service Offering 2Accuray Announces New Treatment Planning Service Offering 3Accuray Announces New Treatment Planning Service Offering 4Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 2Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 3
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Athens, Ga. Companion animals that have a long-term need ... top-selling antiplatelet drug marketed to humans: clopidogrel, commonly known ... Georgia College of Veterinary Medicine have found ,that clopidogrel may ... long-term anticoagulant therapy. In addition, it may offer a ...
... Associate Professor at The City College of New York (CCNY), have ... water so that it can be scooped up like the fat ... soup. The agent could potentially be used to recover oil lost ... Professor John said. In the laboratory, Professor John and colleagues ...
... in cities, disposing of garbage and recycling anything that ... city and cell, health problems can arise when the ... of Michigan cell biologist Haoxing Xu and colleagues reveals ... recycling center, the lysosome, functions. These insights, which may ...
Cached Biology News:Plavix may be treatment for dogs at risk of thromboembolic disease 2Opening the gate to the cell's recycling center 2